Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease

  • Dimitrios Kapogiannis
  • , Adam Boxer
  • , Janice B. Schwartz
  • , Erin L. Abner
  • , Arya Biragyn
  • , Umesh Masharani
  • , Lynda Frassetto
  • , Ronald C. Petersen
  • , Bruce L. Miller
  • , Edward J. Goetzl

Producción científica: Articlerevisión exhaustiva

303 Citas (Scopus)

Resumen

Insulin resistance causes diminished glucose uptake in similar regions of the brain in Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2). Brain tissue studies suggested that insulin resistance is caused by low insulin receptor signaling attributable to its abnormal association with more phospho (P)-serine-type 1 insulin receptor substrate (IRS-1) and less P-tyrosine-IRS-1. Plasma exosomes enriched for neural sources by immunoabsorption were obtained once from 26 patients with AD, 20 patients with DM2, 16 patients with frontotemporal dementia (FTD), and matched case control subjects. At 2 time points, they were obtained from 22 others when cognitively normal and 1 to 10 yr later when diagnosed with AD. Mean exosomal levels of extracted P-serine 312-IRS-1 and P-pantyrosine-IRS-1 by ELISA and the ratio of P-serine 312-IRS-1 to P-pan-tyrosine-IRS-1 (insulin resistance factor, R) for AD and DM2 and P-serine 312-IRS-1 and R for FTD were significantly different from those for case control subjects. The levels of R for AD were significantly higher than those for DM2 or FTD. Stepwise discriminant modeling showed correct classification of 100% of patients with AD, 97.5% of patients with DM2, and 84% of patients with FTD. In longitudinal studies of 22 patients with AD, exosomal levels of P-serine 312-IRS-1, P-pan-tyrosine-IRS-1, and R were significantly different 1 to 10 yr before and at the time of diagnosis compared with control subjects. Insulin resistance reflected in R values from this blood test is higher for patients with AD, DM2, and FTD than case control subjects; higher for patients with AD than patients with DM2 or FTD; and accurately predicts development of AD up to 10 yr prior to clinical onset.

Idioma originalEnglish
Páginas (desde-hasta)589-596
Número de páginas8
PublicaciónFASEB Journal
Volumen29
N.º2
DOI
EstadoPublished - feb 1 2015

Nota bibliográfica

Publisher Copyright:
© FASEB.

Financiación

FinanciadoresNúmero del financiador
Alzheimer's Association
Association for Frontotemporal Degeneration
Bristol-Myers Squibb
Genentech Incorporated
Mayo Clinic Rochester
National Institute on Aging
Pfizer
National Institute on AgingZIAAG000975

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Biotechnology
    • Biochemistry
    • Molecular Biology
    • Genetics

    Huella

    Profundice en los temas de investigación de 'Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease'. En conjunto forman una huella única.

    Citar esto